INT184749

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 9.45
Pain Relevance 0.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lyase activity (Car9) plasma membrane (Car9)
Anatomy Link Frequency
vasculature 1
H69 1
Car9 (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 28 92.16 High High
Inflammation 3 75.04 Quite High
adenocard 2 60.88 Quite High
Antiemetics 1 57.80 Quite High
palliative 5 21.28 Low Low
Central nervous system 8 5.00 Very Low Very Low Very Low
anesthesia 6 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
Kinase C 2 5.00 Very Low Very Low Very Low
ketamine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypoxia 141 99.98 Very High Very High Very High
Cancer 949 99.80 Very High Very High Very High
Pancreatic Cancer 20 98.60 Very High Very High Very High
Adenocarcinoma 35 98.28 Very High Very High Very High
Renal Cell Carcinoma 100 97.52 Very High Very High Very High
Disease 93 95.36 Very High Very High Very High
Colon Cancer 25 94.88 High High
Toxicity 57 92.60 High High
Non-small-cell Lung Cancer 37 90.16 High High
Small Cell Lung Carcinoma 10 79.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While very few cells were found to be CAIX positive in smaller H69 tumors (<1000 mg, Figure 1(f(a))), the larger H69 tumors (>2000 mg, Figure 1(f(b))) had the characteristic perinecrotic hypoxia.
Gene_expression (positive) of CAIX in H69 associated with hypoxia and cancer
1) Confidence 0.31 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2860580 Disease Relevance 0.92 Pain Relevance 0
Figures 6(g) and 6(j) show typical distribution of tumor MVD (arrow, brown) with regions of hypoxia stained for CAIX (Figure 6(k), arrow, brown) and HIF-1?
Gene_expression (stained) of CAIX associated with hypoxia and cancer
2) Confidence 0.31 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2860580 Disease Relevance 1.98 Pain Relevance 0
Figures 6(a) and 6(d) shows the representative tumor vascular distribution (arrow, brown) in poorly and well differentiated HNSCC with regions of hypoxia stained for CAIX immunostaining (Figures 6(b) and 6(e)) and HIF-1?
Gene_expression (stained) of CAIX associated with hypoxia and cancer
3) Confidence 0.31 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2860580 Disease Relevance 1.70 Pain Relevance 0
Figures 6(a) and 6(d) shows the representative tumor vascular distribution (arrow, brown) in poorly and well differentiated HNSCC with regions of hypoxia stained for CAIX immunostaining (Figures 6(b) and 6(e)) and HIF-1?
Gene_expression (immunostaining) of CAIX associated with hypoxia and cancer
4) Confidence 0.31 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2860580 Disease Relevance 1.75 Pain Relevance 0
Immunostaining of tumor vasculature in the TMAs was done using antihuman CD34 (DAKO, Carpinteria, CA) used at 1/50 dilution for 90 minutes at room temperature followed by 30 minutes incubation with Streptavadin complex (Zymed Lab, Inc., San Francisco, CA) as per methods described earlier [5–7]; CAIX immunostaining, the primary antibody M75 (gift from Dr Pastorek, Institute of Virology, Slovak Republic) was used at 20??
Gene_expression (immunostaining) of CAIX in vasculature associated with cancer
5) Confidence 0.31 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2860580 Disease Relevance 0.24 Pain Relevance 0
In addition, CA19-9 levels were measured every eight weeks.
Gene_expression (levels) of CA19-9
6) Confidence 0.13 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1180427 Disease Relevance 0.52 Pain Relevance 0.11
For example, carbonic anhydrase IX expression has been reported as a predictor of outcome in patients with RCC receiving IL-2-based therapy (Atkins et al 2005) and microarray technology has been used to classify RCCs (Kosari et al 2005; Yang et al 2005).
Gene_expression (expression) of anhydrase IX associated with renal cell carcinoma
7) Confidence 0.05 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.75 Pain Relevance 0
Careful patient selection for such therapy is vital: recent data suggest that high tumor carbonic anhydrase IX (Atkins et al 2005) expression is predictive of prolonged median survival after IL-2-based therapy; this antigen therefore may be a useful marker in selecting patients for therapy, but there is a clear need for effective treatment options in the majority of patients who do not benefit from immunotherapy.


Gene_expression (expression) of anhydrase IX associated with cancer
8) Confidence 0.03 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.76 Pain Relevance 0.03
Because CEA and CA19-9 are expressed in up to 98% and 91% of pancreatic ductal adenocarcinomas, respectively [22], the clinical application of fluorophore-conjugated antibodies directed against them should allow identification of almost all pancreatic adenocarcinoma lesions.
Gene_expression (expressed) of CA19-9 associated with adenocarcinoma
9) Confidence 0.01 Published 2010 Journal Surg Endosc Section Body Doc Link PMC3003784 Disease Relevance 0.85 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox